TW434016B - Pharmaceutical tablet containing famciclovir and a process for its preparation - Google Patents
Pharmaceutical tablet containing famciclovir and a process for its preparation Download PDFInfo
- Publication number
- TW434016B TW434016B TW086100335A TW86100335A TW434016B TW 434016 B TW434016 B TW 434016B TW 086100335 A TW086100335 A TW 086100335A TW 86100335 A TW86100335 A TW 86100335A TW 434016 B TW434016 B TW 434016B
- Authority
- TW
- Taiwan
- Prior art keywords
- patent application
- scope
- pharmaceutical
- lactose
- item
- Prior art date
Links
- 229960004396 famciclovir Drugs 0.000 title claims abstract 8
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 title claims abstract 8
- 238000000034 method Methods 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 3
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000003826 tablet Substances 0.000 claims description 24
- 239000007937 lozenge Substances 0.000 claims description 13
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 229960001375 lactose Drugs 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 229960004977 anhydrous lactose Drugs 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 230000002079 cooperative effect Effects 0.000 claims description 3
- 229940023144 sodium glycolate Drugs 0.000 claims description 3
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000015170 shellfish Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 241000736199 Paeonia Species 0.000 claims 2
- 235000006484 Paeonia officinalis Nutrition 0.000 claims 2
- 239000007767 bonding agent Substances 0.000 claims 2
- 239000008043 pharmaceutical bonding agent Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 5
- -1 penciclovir compound Chemical class 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 241000209761 Avena Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- FMDLISAHAFBTRH-UHFFFAOYSA-J C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Re+4].C(CCCCCCCCCCCCCCCCC)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[O-] Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Re+4].C(CCCCCCCCCCCCCCCCC)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[O-] FMDLISAHAFBTRH-UHFFFAOYSA-J 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- UDWXLZLRRVQONG-UHFFFAOYSA-M sodium hexanoate Chemical compound [Na+].CCCCCC([O-])=O UDWXLZLRRVQONG-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
^34016 - A7 B7_ 五、發明説明（1 ) 本發明係關於一種新穎醫藥產物調配物。 ^---ί--^------ (請先閱讀背面之注^^項再填寫本莧) 欧洲專利182024號（發給Beecham Group p.Lc.的）實例2説 明製備法西克樂維耳的方法，法西克樂維耳爲盤西克樂維 耳（penciclovir)化合物經口使用的化合物，盤西克樂維耳具 抗病毒活性，可用於對抗由疱疹病毒引起的感染，如I型單 純性疮療，II型單純性疱奢，及水痘帶狀疮療病毒，也可 用於對抗B型肝炎病毒。盤西克樂維耳及其抗病毒活性見 "Abstracts of 14th Int. Congress of Microbiology" » Manchester，England 7-13 September 1986之摘要P·VI 1_5， p. 193 (Boyd', etal·〉所揭示。 法西克樂維耳較佳是以含125毫克，250毫克，500毫克 或750毫克活性成分的錠劑給予。如一般習用錠劑一樣， 此錠劑含賦形劑，如乳糖，瀝粉己醉酸鈉及硬脂酸嫫，賦 形劑總量至少爲15 %。一般以無水乳糖爲主要的賦形劑， 以使活性成分的性質在打片過程中不會起改變。 賦形劑的含量越高，任一给予劑量的錠的大小會越大。 特別是含活性劑500毫克及750毫克時的錠劑，在錠劑含約 76%法西克樂維耳時，其卵圓形面積分別爲18毫米χ8.5毫 米及21毫米xlO毫米，這麼大的錠會使病人抱怨。 鯉濟部中央揉率局貝工消费合作社印製 現已發現，可將法西克樂維耳調配成含賦形劑少於15 % 的錠劑，在此範面内不會使法西克樂維耳的打片性質發生 改變。 因之，本發明提供一種醫藥錠劑，其中法西克樂維耳爲 活性成分，且其中法费克樂维耳的重量百分比爲錠的85% -4- 本紙張尺度適用中國國家標準（CNS ) Α4規格（210Χ297公釐） 434016 A7 B7 經濟部中央標率局員工消費合作社印装 五、發明説明（2 或更大。 此處所給予的重量百分比値’除非另有説明，以任何 錠劑核重量爲準，此錠劑核可作塗覆，例如作膜塗覆。 逋宜的錠劑含少於15%，少於10%，少於5〇/〇，較佳是 0%的乳糖或其他類似軾形劑，如微結晶纖維素β 適宜的錠劑所含法西克樂維耳的重量百分比大於85〇/〇， 86%，87°/。，88%，89%，90% 或 91%。較佳是含盡可能 高重量百分比的法西克樂維耳。法西克樂維耳可爲逋宜的 醫藥上可接受的形式，例如鹽的形式，溶劑化物或多晶形 物的形式》 錠劑組合物中所含習用的賦形劑包括羥两基纖維素，達 例如5%或達3 %，爽粉乙醇酸納，達例如15%，10%，7% ，或5%，及硬脂酸鎂達例如2%或1 % » 錠劑可用遑於醫藥錠劑用的塗復做塗後》 此等錠劑可以技藝已知的習用方法·製備。較佳的方法是 ，將法西克樂維耳用賦形剗，例如羥丙基纖維素，製成顆 粒，以使活性成分因物理形狀的任何改變的影響減至最低 。將顆粒縴過，乾燥，然後於另外的賦形劑混合，製成打 片混合物。錠劑係打成遑於所需劑量的大小於重量，然後 視需要做塗覆。 下述實例説明本發明》 實例 括號内之百分比値爲在大不列類聯合王國及北愛爾蘭， 美S及其他世界各國醫藥管理當局登記之法西克樂維耳錠 -5. 本紙張尺度適用中國國家揉率（CNS ) A4規格（210X297公釐） {請先閱讀背面之注項再填寫本頁) ，τ r 4 3 4016、 Α7 Β7 五、發明説明（3 ) 的百分比值。 成分 %重量/重量 β/。重量/1 法西克樂維耳 91.42 (75.66) 羥丙基纖維素 2.83 (2.34) 澱粉G醇酸鈉 5.00 (5.00) 硬脂酸鎂 0.75 (0_75) 無水乳糖 0 (16.25) 500毫克劑量的錠核重爲近5 47毫克，750毫克劑量的錠 核重爲近820毫克》 作成塗覆錠時，塗覆增加錠核重的2.5%，500毫克劑量 的塗覆錠重爲560毫克，750毫克劑量的塗覆錠重爲840毫 克。 此等錠的製铺是，以法西克樂維耳舆羥丙基纖維素作乾 混合，然後於高剪顆粒器内將混合物舆水製成顆粒。將濕 物質歸過，乾燥，研磨。研磨過的顆粒澱粉乙醇酸鈉及硬 脂酸鎂混合，製成打片混合物。以逍於所需錠劑強度打成 大小及重量適宜的錠，然後作水性膜塗覆》 製成的750毫克的錠的_圓面積爲19毫米x9毫米，5〇0 毫克的錠的卵圓面積爲17毫米χ8毫米。 (請先聞讀背面之注項再填寫本頁) -^夺 訂 經濟部中央橾準局貝工消费合作杜印袋 -6- 本紙張尺度適用中國國家揉準（CNS ) A4規格（210 X 297公釐）
Claims (1)
- 434〇 1 6 ^ 86100335號專利申請案 —範圍修正^g88 六、申請專利範圍 A8 B8 HiΜ h 一種醫藥錠#丨，其中活性成分是法西克樂維耳 .(famciclovir)，且其中法西克樂維耳的重量百分比是錠劑 的8 5 0/〇或更多。 2. 根據申請專利範圍第1項之蝥藥錠劑，其含少於15%的乳 糖》 3. 根據申請專利範園第1或2項之醫藥鍵劑，其含少於5%的 乳糖。 4. 根據申請專利範園第1或2項之醫藥鍵劑，其含〇 %的乳糖 5. 根據申請專利範圍第1或2項之醫藥錠劑 維耳的重量百分比是鍵劑的90 %或更多。 6, 根據申請專利範圍第！或2項之醫藥錠劑， 其中法西克樂 其成分如下： (請先閲讀背面之注意事項再填寫本頁) 成分 %^量/重量 法西克樂維耳 91.42 羥丙基纖維素 2.83 澱粉乙醇酸鈉 5.00 硬脂酸鎂 0.75 無水乳糖 0 經濟部中央揉率局貝工消费合作社印裝 7. —種製備根據申請專利範圍第1或2項之錠劑之方法，其 中先將法西克樂維耳與賦形劑製成顆粒，然後壓成錠。 本纸張AA制tBB家搞準〖CNS ) A4iUS· ( 21GX297公釐） 修正 ! \/2： 本、 年月叫1么、一 1 補充 89. 7.13 | »—------一 申請曰期 86.01.14. 案 號 一 .〜— 86100335 類 别 (以上各攔由本局填註） A4 C4 434016 (89年7月修正頁） 翁|專利説明書 _、發明 新型 名稱 1、發明 創作 人 中 文 英 文 姓 名 國 籍 住、居所 姓 名 (名稱） 含法西克樂維耳(famcic丨ovir)之醫藥鍵刺及其製法 PHARMACEUTICAL TABLET CONTAINING FAMCICLOVIR AND A PROCESS FOR ITS PREPARATION 1. 麥可強格林威 2. 珍妮佛瑪莉史菝特 1-2英國 1. 英國西蘇塞郡沃辛市克拉倫敦路史密斯克林貝克曼製藥2. 英國西蘇塞郡沃辛市克拉倫敦路史密斯克林貝克曼製藥 英商史密斯克林貝克曼公司 裝 訂 經濟部智",!|4^段工”費合作社印製 國 藉 英國 三、申请人 住、居所 (事務所） 代表人 姓 名 英國米德萊赛省班特福市新界 大衛.羅伯茲 ^紙張尺度適用中國國家標^ ((：1^)八4规格（210乂297公釐) 434〇 1 6 ^ 86100335號專利申請案 —範圍修正^g88 六、申請專利範圍 A8 B8 HiΜ h 一種醫藥錠#丨，其中活性成分是法西克樂維耳 .(famciclovir)，且其中法西克樂維耳的重量百分比是錠劑 的8 5 0/〇或更多。 2. 根據申請專利範圍第1項之蝥藥錠劑，其含少於15%的乳 糖》 3. 根據申請專利範園第1或2項之醫藥鍵劑，其含少於5%的 乳糖。 4. 根據申請專利範園第1或2項之醫藥鍵劑，其含〇 %的乳糖 5. 根據申請專利範圍第1或2項之醫藥錠劑 維耳的重量百分比是鍵劑的90 %或更多。 6, 根據申請專利範圍第！或2項之醫藥錠劑， 其中法西克樂 其成分如下： (請先閲讀背面之注意事項再填寫本頁) 成分 %^量/重量 法西克樂維耳 91.42 羥丙基纖維素 2.83 澱粉乙醇酸鈉 5.00 硬脂酸鎂 0.75 無水乳糖 0 經濟部中央揉率局貝工消费合作社印裝 7. —種製備根據申請專利範圍第1或2項之錠劑之方法，其 中先將法西克樂維耳與賦形劑製成顆粒，然後壓成錠。 本纸張AA制tBB家搞準〖CNS ) A4iUS· ( 21GX297公釐）
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9600847.9A GB9600847D0 (en) | 1996-01-16 | 1996-01-16 | Pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW434016B true TW434016B (en) | 2001-05-16 |
Family
ID=10787105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW086100335A TW434016B (en) | 1996-01-16 | 1997-01-14 | Pharmaceutical tablet containing famciclovir and a process for its preparation |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US6765007B1 (zh) |
| EP (1) | EP0874632B1 (zh) |
| JP (2) | JP4711360B2 (zh) |
| KR (1) | KR100338829B1 (zh) |
| CN (1) | CN1132582C (zh) |
| AP (2) | AP747A (zh) |
| AR (1) | AR005456A1 (zh) |
| AT (1) | ATE220910T1 (zh) |
| AU (1) | AU713090B2 (zh) |
| BG (1) | BG63488B1 (zh) |
| BR (1) | BR9706982A (zh) |
| CY (1) | CY2390B1 (zh) |
| CZ (1) | CZ287205B6 (zh) |
| DE (1) | DE69714215T2 (zh) |
| DK (1) | DK0874632T3 (zh) |
| DZ (1) | DZ2159A1 (zh) |
| EA (1) | EA001946B1 (zh) |
| EG (1) | EG23684A (zh) |
| ES (1) | ES2180922T3 (zh) |
| GB (1) | GB9600847D0 (zh) |
| HU (1) | HU225472B1 (zh) |
| IL (1) | IL124913A0 (zh) |
| MX (1) | MX9805713A (zh) |
| MY (1) | MY127527A (zh) |
| NO (1) | NO315689B1 (zh) |
| NZ (1) | NZ326769A (zh) |
| OA (1) | OA10812A (zh) |
| PE (1) | PE35498A1 (zh) |
| PL (1) | PL187291B1 (zh) |
| PT (1) | PT874632E (zh) |
| SK (1) | SK282132B6 (zh) |
| TR (1) | TR199800954T2 (zh) |
| TW (1) | TW434016B (zh) |
| UA (1) | UA63897C2 (zh) |
| UY (2) | UY24437A1 (zh) |
| WO (1) | WO1997025990A1 (zh) |
| ZA (1) | ZA97310B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007037790A2 (en) * | 2005-06-08 | 2007-04-05 | Elan Corporation, Plc | Modified release famciclovir compositions |
| CA2765630C (en) | 2009-06-26 | 2016-07-05 | Taris Biomedical, Inc. | Solid drug tablets for implantable drug delivery devices |
| JP2015063521A (ja) * | 2013-09-02 | 2015-04-09 | 科研製薬株式会社 | 高い薬物含有率を有する錠剤及びその製造方法 |
| CN104434852B (zh) * | 2013-09-18 | 2018-11-20 | 北京韩美药品有限公司 | 泛昔洛韦直压片及其制备方法 |
| CN112587491B (zh) * | 2021-01-03 | 2022-08-23 | 迪沙药业集团有限公司 | 一种泛昔洛韦片组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3421800C1 (de) * | 1984-06-12 | 1986-04-17 | Maschinen und Werkzeugbau Michael Brümmer GmbH, 8804 Dinkelsbühl | Elastische Walze zum Behandeln einer thermoplastischen Folie |
| DE3582399D1 (de) * | 1984-09-20 | 1991-05-08 | Beecham Group Plc | Purin-derivate und ihre pharmazeutische verwendung. |
| FI20021701L (fi) * | 1991-01-30 | 2002-09-24 | Wellcome Found | Veteen dispergoituvia tabletteja |
| EP0586523A4 (en) | 1991-05-15 | 1995-11-29 | Univ Yale | Determination of prodrugs metabolizable by the liver and therapeutic use thereof |
| GB9303157D0 (en) * | 1993-02-17 | 1993-03-31 | Scotia Holdings Plc | Treatment of a group of related disorders |
| IL111138A (en) | 1993-10-05 | 1997-04-15 | Smithkline Beecham Plc | Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia |
| JP3702594B2 (ja) * | 1997-08-07 | 2005-10-05 | 株式会社明電舎 | パラメータ調節方法及び装置 |
-
1996
- 1996-01-16 GB GBGB9600847.9A patent/GB9600847D0/en active Pending
-
1997
- 1997-01-02 AP APAP/P/1997/000911A patent/AP747A/en active
- 1997-01-10 UY UY24437A patent/UY24437A1/es not_active IP Right Cessation
- 1997-01-13 DK DK97901539T patent/DK0874632T3/da active
- 1997-01-13 AT AT97901539T patent/ATE220910T1/de active
- 1997-01-13 DE DE69714215T patent/DE69714215T2/de not_active Expired - Lifetime
- 1997-01-13 US US09/101,926 patent/US6765007B1/en not_active Expired - Lifetime
- 1997-01-13 IL IL12491397A patent/IL124913A0/xx not_active IP Right Cessation
- 1997-01-13 EA EA199800573A patent/EA001946B1/ru not_active IP Right Cessation
- 1997-01-13 UA UA98063199A patent/UA63897C2/uk unknown
- 1997-01-13 KR KR1019980705371A patent/KR100338829B1/ko not_active Expired - Lifetime
- 1997-01-13 PL PL97327922A patent/PL187291B1/pl unknown
- 1997-01-13 WO PCT/EP1997/000195 patent/WO1997025990A1/en not_active Ceased
- 1997-01-13 HU HU9901021A patent/HU225472B1/hu unknown
- 1997-01-13 ES ES97901539T patent/ES2180922T3/es not_active Expired - Lifetime
- 1997-01-13 AP APAP/P/1998/001298A patent/AP1114A/en active
- 1997-01-13 JP JP52569297A patent/JP4711360B2/ja not_active Expired - Lifetime
- 1997-01-13 TR TR1998/00954T patent/TR199800954T2/xx unknown
- 1997-01-13 CZ CZ19982254A patent/CZ287205B6/cs not_active IP Right Cessation
- 1997-01-13 AU AU15418/97A patent/AU713090B2/en not_active Expired
- 1997-01-13 SK SK956-98A patent/SK282132B6/sk not_active IP Right Cessation
- 1997-01-13 CN CN97191703A patent/CN1132582C/zh not_active Expired - Lifetime
- 1997-01-13 NZ NZ326769A patent/NZ326769A/xx not_active IP Right Cessation
- 1997-01-13 BR BR9706982A patent/BR9706982A/pt not_active IP Right Cessation
- 1997-01-13 PT PT97901539T patent/PT874632E/pt unknown
- 1997-01-13 EP EP97901539A patent/EP0874632B1/en not_active Expired - Lifetime
- 1997-01-14 EG EG4697A patent/EG23684A/xx active
- 1997-01-14 TW TW086100335A patent/TW434016B/zh not_active IP Right Cessation
- 1997-01-14 AR ARP970100130A patent/AR005456A1/es active IP Right Grant
- 1997-01-15 ZA ZA9700310A patent/ZA97310B/xx unknown
- 1997-01-15 DZ DZ970004A patent/DZ2159A1/fr active
- 1997-01-15 PE PE1997000022A patent/PE35498A1/es not_active IP Right Cessation
- 1997-01-15 MY MYPI97000137A patent/MY127527A/en unknown
- 1997-05-16 UY UY24556A patent/UY24556A1/es not_active IP Right Cessation
-
1998
- 1998-07-15 BG BG102638A patent/BG63488B1/bg unknown
- 1998-07-15 MX MX9805713A patent/MX9805713A/es unknown
- 1998-07-15 NO NO19983259A patent/NO315689B1/no not_active IP Right Cessation
- 1998-07-16 OA OA9800116A patent/OA10812A/en unknown
-
2003
- 2003-11-28 CY CY0300085A patent/CY2390B1/xx unknown
-
2008
- 2008-11-19 JP JP2008295818A patent/JP2009091362A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW493984B (en) | Pharmaceutical composition comprising ibuprofen and codeine and preparation thereof | |
| JPS611613A (ja) | 溶解度の低い薬物の経口用薬剤組成物 | |
| WO2022100641A1 (zh) | 包含egfr抑制剂的药物组合物及其制备方法 | |
| TW438608B (en) | A tablet containing anion exchange resin | |
| JP3718341B2 (ja) | 低置換度ヒドロキシプロピルセルロースとその製造方法 | |
| JPS63301820A (ja) | 製薬学的錠剤、製薬学的顆粒及びそれらの製法 | |
| JPH10512564A (ja) | コロイド状二酸化ケイ素を含むバラシクロビール錠剤 | |
| TW508242B (en) | Pharmaceutical composition comprising paracetamol | |
| CN112438979B (zh) | 用于口腔掩味的含氢溴酸沃替西汀的包衣颗粒、固体分散体和制剂 | |
| TW528605B (en) | Anion exchange resin-containing tablets | |
| CN110960501B (zh) | 一种诺氟沙星胶囊及其制备方法 | |
| CN109172534B (zh) | 一种硝苯地平缓释片剂组合物 | |
| JP2009091362A (ja) | 高含量ファムシクロビル錠剤 | |
| US3019169A (en) | Salicylate dry shell coating of dry 4-aminoquinoline core, and dry-compressing tablet-making process | |
| JP2009091362A6 (ja) | 高含量ファムシクロビル錠剤 | |
| CN119564630A (zh) | 一种琥珀酸多西拉敏吡哆醇肠溶片及其制备方法 | |
| AU739466B2 (en) | Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI) | |
| JP4591726B2 (ja) | メキタジン含有内服固形製剤 | |
| EP1079834A1 (en) | Stabile compositions comprising levosimendan and alginic acid | |
| JPS6346726B2 (zh) | ||
| CN100435804C (zh) | 司他夫定口服速释制剂及制备方法 | |
| CN100435797C (zh) | 茚地那韦口服速释制剂及制备方法 | |
| JPH07277962A (ja) | グアイフェネシン配合製剤 | |
| JPWO2004039408A1 (ja) | 医薬組成物 | |
| JPS6383025A (ja) | 低置換ヒドロキシプロピルセルロースを含有するアスピリン、アセトアミノフェン及びカフェインの鎮痛薬錠剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MK4A | Expiration of patent term of an invention patent |